THE LATEST FROM US

News archive

StatFinn and EPID Research present strong growth in 2016

11.04.2017 – StatFinn and EPID Research achieved strong and profitable growth in 2016. Following the 2-digit growth from the previous financial year, the results show that the merged company continues the global expansion with solid basis, resources and talent. Read more details in the officia...

New article on insulins and risk of severe hypoglycemia

17.2.2017 – Our new article on insulins NPH, glargine, and detemir, and risk of severe hypoglycemia has been published in Annals of Medicine. The comparative safety of modern basal insulins regarding hypoglycemia among the working-age population has been unclear. Large reductions in the inci...

Attendance at ISPE’s 2017 Mid-Year Meeting

15.2.2017 – EPID Research is proud to sponsor ISPE’s 2017 Mid-Year Meeting in London. ISPE, the International Society for Pharmacoepidemiology, is a non-profit international professional membership organisation dedicated to advancing the health of the public. We look forward to meeting...

Our Swedish branch moved to a new office

1.2.2017 – Our business is growing and new talented people have joined us. Therefore, our Swedish branch has moved to a new office in Little Bommen, Gothenburg. The new address is: EPID Research Sweden branch Little Bommen 6, 7th Floor SE-411 04 Gothenburg, Sweden   For more information, ple...

StatFinn and EPID Research join forces

16.01.2017 – StatFinn and EPID Research have decided to merge their operations in order to offer a full range of services to their clients in clinical data analytics and Real-World Evidence from Phase I to Phase IV and beyond. The combined company employs over 70 experts with presence in five ...

New article on cardiovascular medicine

23.11.2016 – Our new article on cardiovascular medicine has been published in BMJ Open. Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland. Published in B...

Head office expanded and open positions

5.10.2016 – EPID Research is growing. We recently renewed and expanded our head office in Espoo. Now we are looking for new talented people to join us. We currently have the following positions open: Director – Real-World Evidence, Pharmacoepidemiologist and Study Coordinator.   &nb...
Are you interested in learning more about how our RWE solutions can help you in your drug development and surveillance? Our team of experts is eager to discuss your specific needs. To learn more, please contact us at office@epidresearch.com.